News Center

Home page

Peak Report

News reports

Small Molecule Targeted Drug Research Institute Established

Release time:

2020-08-14

Small Molecule Targeted Drug Research Institute Established

News 9# July 13 On the morning of the 9th, the listing ceremony of Anhui Jianfeng Beika Pharmaceutical Small Molecule Targeted Drug Research Institute was held in the Dongzhi Economic Development Zone of Anhui Province.

Dongzhi County Party Secretary Li Mingyue, County Mayor Sheng Guoxing, Chairman of the Group Company and Chairman of the Pharmaceutical Company Jiang Xiaomeng, and Lu Wei, founder of Shanghai Beika Pharmaceutical Company and professor of the Institute of Medicine of the Chinese Academy of Sciences, jointly unveiled the institute (right picture).

Sheng Guoxing County Chief pointed out in his speech at the listing site that the establishment of Anhui Jianfeng Beika Pharmaceutical Small Molecule Targeted Drug Research Institute is an attempt and exploration to deepen innovation drive and carry out industry-university-research cooperation. He hopes that Jianfeng Group will continue to increase investment in funds and talents, integrate scientific research resources, give full play to the innovative advantages of the research institute, and build the small molecule targeted drug research institute into a research institute with strong academic atmosphere, close industry-university-research cooperation, and remarkable scientific and technological achievements. He asked the Dongzhi Economic Development Zone Management Committee and relevant units directly under the county to make every effort to serve and ensure the construction and operation of the research institute, and through the joint efforts of all parties, the Dongzhi Economic Development Zone will be built into a highland of scientific and technological innovation, so that the park will bloom with science and technology. Flowers, bear the fruit of industry. Jiang Xiaomeng, chairman of

group company, delivered a speech at the listing ceremony of the research institute. He said that Shanghai North Carolina Pharmaceutical Company is a holding subsidiary of Jianfeng Group. It is a high-tech enterprise in Shanghai, a "specialized and new" technology enterprise in Shanghai, and a "Shanghai patent pilot enterprise". It has an academician expert workstation and Songjiang District "Enterprise Technology Center", and has a number of "Shanghai High-tech Achievement Transformation Project" results. The products mainly include intermediates such as small molecule targeted and alkaloid anti-tumor drugs. The company takes Shanghai Beika as the research and development and market highland, and takes Jianfeng Beika Pharmaceutical as the link of technology and variety transformation. The research and development results and industrialization results are produced and sold by two factories of Anhui Xinbeika Chemical and Anhui Zhongwang Pharmaceutical, and a small molecule targeted drug manufacturing base is built in Dongto Economic Development Zone. In order to better develop small molecule targeted drugs, with the assistance of Dongzhi County Party Committee and Economic Development Zone, a small molecule targeted drug research institute was established to speed up the progress of scientific and technological innovation and technological transformation, and realize the industrialization of small molecule targeted drug products as soon as possible. At the same time, the Small Molecule Targeted Drug Research Institute will also rely on the technical support of three academicians and experts of Jianfeng Pharmaceutical and four postdoctoral workstations, and cooperate with the Chinese Academy of Sciences, China Pharmaceutical University, Fudan University, Shanghai Molecular Therapy and New Drug Creation Engineering Technology Research Center and other scientific research institutions to establish long-term industry-university-research cooperation, in accordance with the principle of "innovation, creation, creation" and strive to create "green environmental protection, top technology, for the benefit of human health" high-end scientific research institutions. After the opening ceremony of

, Li Mingyue, Secretary of Dongzhi county Party committee, was interviewed by Jinhua Daily. While congratulating Jianfeng group on the 23rd anniversary of its establishment 60#, he said that Dongzhi county government and relevant departments will give maximum support and service to the small molecule targeted drug research institute, and ensure the construction and operation of the research institute, We hope that the Institute can give full play to its advantages and strive to achieve remarkable results as soon. (Ni Yingzhen Zhang Feifei)

News Link:

Small molecule drugs mainly refer to chemically synthesized drugs with molecular weight less than

1000 . The structure of small molecule drugs has good spatial dispersion, and its chemical properties determine its good pharmaceutical properties and pharmacokinetic properties. Small molecule drugs are usually signal transduction inhibitors, which can specifically block the signal transduction pathway necessary for tumor growth and proliferation, so as to achieve the purpose of treatment.

For ordinary drugs, only a very small part of them can really act on the lesion after entering the body. This is the root cause of restricting drug efficacy and leading to drug side effects. A targeted drug (also referred to as a targeting agent) refers to a drug or formulation thereof that is endowed with the ability to target (

Targeting ). The purpose is to target the drug or its carrier at a specific lesion site and to accumulate or release the active ingredient at the target site. Targeted preparations can make the drug form a relatively high concentration in the target area, thereby improving the efficacy of the drug while inhibiting toxic side effects and reducing the damage to normal tissues and cells.

More information

The company fully deploys 2018 work

On January 27, the group company held a business analysis meeting to review and summarize the work in 2017, arrange and deploy the work for the new year, and put forward work requirements. At the meeting, various professional companies and directly affiliated enterprises reported on the overall work situation in 2017, focusing on analyzing the existing problems and deficiencies, and proposing corresponding solutions and work plans for 2018. Xiang Chongping, deputy general manager of the group company, systematically combed the current human resources efficiency and human resources development of the company. Chen Tianci, chairman of the board of supervisors, made a report and analysis on the "three reductions and three improvements" and the safety and environmental protection work in 2017. Lan Xiaolong, head of finance, analyzed the risks and challenges currently faced by the company according to the operating data and financial situation of its subordinate enterprises. The functional departments and offices of the headquarters also made a brief report on their annual work. Yu Jianhong, general manager of the group company, made a comprehensive review of the company's operation in 2017, compared and analyzed the main economic indicators of various industrial sectors, and pointed out that looking for new investment and development projects around strategic objectives, promoting the optimization of organizational structure and post setting, significantly improving the level of information management, improving the ability of fund management and tax planning, achieving certain results in scientific and technological innovation and technological transformation, and strengthening marketing management and market expansion, safety and environmental protection work is basically up to standard, training and talent development have achieved new results and other work highlights; at the same time, it summarizes and reflects on the shortcomings in strategic decision-making, management innovation, performance appraisal, market operation, and talent team building. After analyzing the current macroeconomic situation and the future trends of various related industries, Yu Jianhong informed

2020

07-31

Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base

News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals

2020

07-30

Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base

2020

07-31

Jianfeng Pharmaceutical was rated as a provincial trademark brand demonstration enterprise

On December 28, 2017, Zhejiang Administration for Industry and Commerce announced the list of trademark brand demonstration counties (cities, districts), demonstration towns (streets) and demonstration enterprises in Zhejiang Province in 2017. Jianfeng Pharmaceutical Company was identified as a trademark brand demonstration enterprise, and it was also the only enterprise in Jinhua City to enter the list. Peak Pharmaceutical was established in 1998 and obtained the first registered trademark in 1999. Since then, Jianfeng Pharmaceutical has been actively carrying out brand building in accordance with the requirements of the Trademark Law and other laws and regulations, and has set up an intellectual property department to carry out trademark management, rights protection and other activities; it has established a sound trademark management system, strictly in accordance with the provisions of the Trademark Law to supervise and manage the use of trademarks inside and outside the enterprise, and safeguard the legitimate rights and interests of the enterprise. Establish strategic cooperation with professional institutions, for trademark applications, renewals and other work. In recent years, Jianfeng Pharmaceutical has also explored trademark investment, creating value through intangible assets such as trademarks and brands, promoting efficiency improvement, and further expanding corporate influence; at the same time, it has continuously increased investment in new product research and development and technological transformation, and actively Declare various patents to provide strong support for brand building with technological innovation. According to incomplete statistics, Jianfeng Pharmaceutical and its subsidiaries currently have more than 120 valid trademarks, including 1 well-known trademark in China, 2 well-known trademarks in Zhejiang Province, 5 well-known trademarks in Jinhua City, and 2 overseas registered trademarks; Obtained more than 40 domestic and international patents. Trademark is an important part of intellectual property rights, in the knowledge economy, brand effect is increasingly becoming the leading force of economic development.

2020

07-31

Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base

2020

07-31

The company was rated as an advanced unit of the city's focus on talent and love talent.

News from our newspaper On December 11, the Talent Work Leading Group of the Jinhua Municipal Committee of the Communist Party of China commended the advanced units of Jinhua City that value talents and love talents. 36 units including Jianfeng Group won this honor. The selection of advanced units that value talents and love talents is a measure taken by the Jinhua Municipal Party Committee to further create a good atmosphere of focusing on talents and loving talents, fully respect and make good use of the first resource of talents, serve innovation to drive development, and implement the development strategy of strengthening the province with talents and innovation. The enterprises and institutions that have won this honorary title have always regarded talents as the fundamental driving force for development for a long time, regarded the investment of talents as the most effective investment, and integrated the love of talents into the unit culture. Remarkable achievements have been made in gathering talents, achieving talents, transforming and upgrading, and accelerating development. The Jinhua Municipal Party Committee requires the majority of employers to learn from advanced units, vigorously promote the trend of focusing on talents and loving talents, remove the obstacles to the talent development system and mechanism, and in accordance with the requirements of "walking in the forefront and jointly building Jinhua", in order to promote the construction of a modern metropolitan area and accelerate the construction of the province An important growth pole for high-quality development provides talent support and intellectual guarantee. (this newspaper reporter)

2020

07-31

< 1...38 39 40...61 > 跳转到页